Citigroup says AstraZeneca's (AZN) additional three weeks of data on AZD9291 shows less potency, more rash/diarrhea and no dose response for AZD9291. Citi believes the data shows that the AstraZeneca drug is not "CO-1686 killer that investors were worried about." Clovis (CLVS) makes CO-1686. Citi still thinks the lung cancer market is big enough for both drugs and keeps a Buy rating on Clovis with a $109 price target.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Walmart's CEO went from earning $6.50 an hour to $25 million a year—here are his three tips for climbing the corporate ladder like him
Donald Trump’s aides have drawn up secret plans to oust the chairman of the Federal Reserve and allow the president to set interest rates, according to reports.
The property report includes 85 major metropolitan areas in the U.S. with populations of at least 750,000.
These proven wealth builders could be exactly what you're searching for right now.
"We are not very ambitious. I should be careful about talking about work-life balance, but the Americans just work harder.”
Here's what could happen next to Microsoft shares.
Jamie Dimon and Jerome Powell are taking the European viewpoint on soaring debt levels in the U.S.
Since 2021, Dogecoin (DOGE) has consistently been one of the largest cryptocurrencies in the market. The token has attracted tens of billions in investment and is up more than 27,000% since its launch. While the price has fallen considerably since highs, the token has held its own and performed well in 2024. Some do not see the growth stopping anytime soon. According to some analysts, DOGE could reach — and even surpass — the $100 mark. Don't Miss: Dogecoin millionaires are increasing — investor
It's possible to construct a winning long-term investment strategy with just low-cost index funds.
